Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting HER2 Epitopes.

Sumanta Kumar Pal1, Mark Pegram

  • 1Division of Hematology-Oncology, Department of Medicine, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA. spal@mednet.ucla.edu

Seminars in Oncology
|August 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors.

Cancer research communications·2026
Same author

Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial Availability.

Cancers·2026
Same author

Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced Senescence.

bioRxiv : the preprint server for biology·2026
Same author

International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma.

Frontiers in oncology·2026
Same author

Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing <i>ALK</i> Alteration Prolongs Treatment Duration.

JCO precision oncology·2026
Same author

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

European urology·2026
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Targeting the HER2 receptor, a key factor in many cancers, involves various therapies. Monoclonal antibodies, peptidomimetics, and RNA aptamers inhibit cancer cell growth, with potential synergy when combined.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Variable human epidermal growth factor receptor 2 (HER2) expression is crucial in several cancers.
  • Targeted therapies aim to inhibit HER2 and its downstream signaling pathways.

Purpose of the Study:

  • To review HER2-targeting agents including monoclonal antibodies, peptidomimetics, and RNA aptamers.
  • To explore the potential synergistic interactions of these agents.

Main Methods:

  • Literature review of HER2-targeting therapeutic modalities.
  • Analysis of experimental data on antibody, peptidomimetic, and aptamer efficacy.
  • Examination of recent findings on combination therapy interactions.

Main Results:

Related Experiment Videos

  • Monoclonal antibodies (trastuzumab, pertuzumab) and peptidomimetic agents inhibit HER2-positive cancer cell growth.
  • RNA aptamers also bind HER2 extracellular epitopes, leading to growth inhibition.
  • Experimental models suggest synergistic effects when HER2-targeting agents are combined.

Conclusions:

  • HER2-targeting agents offer diverse mechanisms for inhibiting cancer progression.
  • Combination therapies may enhance efficacy through synergistic interactions.
  • Further research into combined HER2-targeted treatments is warranted.